Korean Circ J.  2009 Nov;39(11):459-461. 10.4070/kcj.2009.39.11.459.

Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation

• Kim JY

• KMID: 2225647
• DOI: http://doi.org/10.4070/kcj.2009.39.11.459

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus
Stents
Ticlopidine
Ticlopidine

Reference

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002. 8:1227–1234.

2. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002. 288:2411–2420.

3. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003. 26:2181–2188.

4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005. 54:2430–2435.

5. Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double antiplatelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J. 2009. 39:462–466.

6. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988. 36:313–320.

7. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008. 29:2202–2211.

8. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005. 46:1833–1837.

9. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007. 28:1814–1819.

10. Angiolillo DJ, Shoemaker SB, Desai B, et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (Optimizaing anti-Platelet Therapy In diabetes MellitUS) study. Circulation. 2007. 115:708–716.

11. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007. 153:66e9–e16.

12. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006. 27:1038–1047.

13. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother. 2006. 40:925–930.

14. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2007. 357:2001–2015.